George Church

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

Retrieved on: 
Monday, March 4, 2024

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.
  • The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
  • Mr. Ahlstedt’s presentation will highlight recent technical developments, and upcoming milestones, on the company’s proprietary enzymatic RNA oligonucleotide synthesis technology, as part of the Innovation in Manufacturing session at the event.
  • This community, from the beginning, has been supportive of our mission to deliver sustainable RNA at scale.

Generation Lab Emerges from Stealth with Funding Round and Mission to Extend the Human Healthspan – Waitlist for Its Clinically Driven At-Home Aging Test + Personalized Aging Intervention Opens Today

Retrieved on: 
Tuesday, January 30, 2024

The company works with clinicians who can recommend personalized interventions, and Generation Lab can measure the effectiveness of these over time.

Key Points: 
  • The company works with clinicians who can recommend personalized interventions, and Generation Lab can measure the effectiveness of these over time.
  • These diseases are a major cause of morbidity and mortality and place a significant burden on our healthcare system.
  • Moreover, the biological age is quantified by Generation Lab for each function of the body: inflammation, regeneration, homeostasis, reproduction, etc.
  • After subsequent Generation Lab tests, your clinician can review how effective each intervention was and its impact on your health and rate of aging.

Frontier Bio Leads Medical Innovation with "Lab-Grown" Blood Vessel Technology for Replacing Animal Testing

Retrieved on: 
Tuesday, October 24, 2023

At present, vascular medical devices must be assessed for safety and performance using animal studies, prior to any testing in human subjects.

Key Points: 
  • At present, vascular medical devices must be assessed for safety and performance using animal studies, prior to any testing in human subjects.
  • By introducing lab-grown vessels, Frontier Bio is championing a future where reliance on such animal testing is significantly reduced, if not eliminated.
  • As proof-of-concept, working with Mayo Clinic, Frontier Bio created a tissue-engineered blood vessel with an aneurysm and deployed a vascular flow diverter device into it.
  • George Church, a renowned geneticist and advisor to Frontier Bio, commented, "Frontier Bio is doing more than just creating lab-grown human tissues.

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

Retrieved on: 
Friday, October 20, 2023

The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.

Key Points: 
  • The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
  • The poster presentation is entitled “A Platform for Controlled Enzymatic Synthesis of RNA Oligonucleotides“ and will be delivered by Dominic Rainone, an Associate Scientist at EnPlusOne Biosciences, during Poster Session 1, which begins at 17:00 on October 23rd.
  • Additional technical data from this poster can also be found in EnPlusOne’s recent manuscript pre-print available online.
  • Likewise, we’ve been very strong supporters of OTS and its mission to bring the field of oligonucleotides to its full therapeutic potential.

GEORGE CHURCH, JULIE CLAUSS JOIN UNRAVEL BIOSCIENCES ADVISORY BOARD

Retrieved on: 
Thursday, September 14, 2023

BOSTON, Sept. 14, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the addition of Prof. George Church and Ms. Julie Clauss to its Advisory Board.

Key Points: 
  • BOSTON, Sept. 14, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the addition of Prof. George Church and Ms. Julie Clauss to its Advisory Board.
  • George Church, Ph.D. is a renowned geneticist and entrepreneur, noted for his integration of new technology with novel scientific questions focused on improving health.
  • Julie Clauss, MEng, MS, MBA is an experienced global pharma executive with 17+ years of experience in senior operating roles.
  • Julie Clauss is a highly accomplished business leader with a remarkable history of driving revenue growth strategies and guiding organizations to realize their vision of improving patient care.

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

Retrieved on: 
Thursday, August 10, 2023

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.

Key Points: 
  • Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
    Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
  • Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
  • Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
  • Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.

ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test

Retrieved on: 
Tuesday, March 7, 2023

Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc. (“Nebula”), has introduced its lowest ever standard price of $249.00 for its direct-to-consumer (DTC) whole genome sequencing (WGS) DNA test.

Key Points: 
  • Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc. (“Nebula”), has introduced its lowest ever standard price of $249.00 for its direct-to-consumer (DTC) whole genome sequencing (WGS) DNA test.
  • “Our mission at Nebula is to usher in a new era of personal genomics by providing access to affordable and secure whole genome sequencing, and today’s announcement marks strong progress toward this goal,” continued Mr. Karkus.
  • Nebula also provides customers with access to over 300 personalized reports based on their genomic profile.
  • Dr. Church has pioneered the development of multiple DNA sequencing methods, including molecular multiplexing approaches that enable next generation sequencing (NGS) as well as nanopore sequencing.

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Retrieved on: 
Wednesday, March 1, 2023

The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.

Key Points: 
  • The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.
  • The funding will also be used to develop its thymic cell engineering platform and expand into additional indications across areas of unmet clinical need in immunology.
  • The thymus is a critical organ in the immune system that regulates and develops T cells, which are essential for fighting infection and disease, along with mounting effective responses to vaccines.
  • Thymmune has also received funding via Wellcome Leap’s inaugural HOPE program, along with an NIH/NIAID Fast-Track SBIR.

EnPlusOne Biosciences Expands Scientific Advisory Board

Retrieved on: 
Wednesday, February 8, 2023

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.
  • Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field.
  • Daniel Wiegand, MSChE, CEO of EnPlusOne said, “We are delighted to attract an experienced, respected researcher like Jon to our Scientific Advisory Board.
  • He serves on the Editorial Boards of Nucleic Acid Therapeutics and Nucleic Acids Research in addition to the Scientific Advisory Council of the OTS.

Colossal Biosciences Secures $150M Series B and Announces Plan to De-Extinct the Iconic Dodo

Retrieved on: 
Tuesday, January 31, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230131005411/en/
    Dr. Beth Shapiro, Ph.D. (Lead Paleogeneticist and Colossal Scientific Advisory Board Member) and Ben Lamm (Colossal Co-Founder and CEO).
  • Since launching in September 2021, Colossal has raised $225M in total funding.
  • Colossal is on a mission to reverse these staggering statistics through genetic rescue techniques and its de-extinction toolkit.
  • Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth.